The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
Open accessAbstract
BACKGROUND: Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13) has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly. However, an increase in disease due to non-vaccine types, or serotype replacement, has been observed. Serotypes' individual contributions to IPD play a critical role in determining the overall effects of PCVs. This study examines the distribution of pneumococcal serotypes in children to identify leading serotypes associated with IPD post-PCV introduction. METHODS: A systematic search was performed to identify studies and surveillance reports (published between 2000 and December 2015) of pneumococcal serotypes causing childhood IPD post-PCV introduction. Serotype data were differentiated based on the PCV administered during the study period: PCV7 or higher valent PCVs (PCV10 or PCV13). Meta-analysis was conducted to estimate the proportional contributions of the most frequent serotypes in childhood IPD in each period. RESULTS: We identified 68 studies reporting serotype data among IPD cases in children. We analysed data from 38 studies (14 countries) where PCV7 was administered and 20 (24 countries) where PCV10 or PCV13 have been introduced. Studies reported early and late periods of PCV7 administration (range: 2001∓13). In these settings, serotype 19A was the most predominant cause of childhood IPD, accounting for 21.8% (95%CI 18.6∓25.6) of cases. In countries that have introduced higher valent PCVs, study periods were largely representative of the transition and early years of PCV10 or PCV13. In these studies, the overall serotype-specific contribution of 19A was lower (14.2% 95%CI 11.1∓18.3). Overall, non-PCV13 serotypes contributed to 42.2% (95%CI 36.1∓49.5%) of childhood IPD cases. However, regional differences were noted (57.8% in North America, 71.9% in Europe, 45.9% in Western Pacific, 28.5% in Latin America, 42.7% in one African country, and 9.2% in one Eastern Mediterranean country). Predominant non-PCV13 serotypes overall were 22F, 12F, 33F, 24F, 15C, 15B, 23B, 10A, and 38 (descending order), but their rank order varied by region. CONCLUSION: Childhood IPD is associated with a wide number of serotypes. In the early years after introduction of higher valent PCVs, non-PCV13 types caused a considerable proportion of childhood IPD. Serotype data, particularly from resource-limited countries with high burden of IPD, are needed to assess the importance of serotypes in different settings. The geographic diversity of pneumococcal serotypes highlights the importance of continued surveillance to guide vaccine design and recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, K. L., Wolfson, L. J., Watt, J. P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O. S., & Cherian, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61204-6 · Cited by 2,398 · cited 7×
“Our review of the literature shows that evidence of the effects of PCV in countries in Asia, Africa, and Eastern Mediterranean is urgently needed to further understand the role of serotypes following PCV10 and PCV13 introduction in settings with high burden of S. pneumoniae disease.”
BackgroundInfluentialSustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Pilishvili, T., Lexau, C., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Reingold, A., Thomas, A., Schaffner, W., Craig, A. S., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/648593 · Cited by 1,311
Serotype replacement in disease after pneumococcal vaccination
Weinberger, D. M., Malley, R., & Lipsitch, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62225-8 · Cited by 1,020
Hicks, L. A., Harrison, L. H., Flannery, B., Hadler, J. L., Schaffner, W., Craig, A. S., Jackson, D., Thomas, A., Beall, B., Lynfield, R., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521626 · Cited by 737
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71081-3 · Cited by 733
Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P., & George, R. C. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70090-1 · Cited by 643
Waight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70044-7 · Cited by 589
Johnson, H. L., Deloria-Knoll, M., Levine, O. S., Stoszek, S. K., Freimanis Hance, L., Reithinger, R., Muenz, L. R., & O'Brien, K. L. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000348 · Cited by 551
Feikin, D. R., Kagucia, E. W., Loo, J. D., Link-Gelles, R., Puhan, M. A., Cherian, T., Levine, O. S., Whitney, C. G., O’Brien, K. L., Moore, M. R., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001517 · Cited by 470 · cited 4×
“to indicate if there has been a change in the absolute number of IPD cases in any given serotype in the post-PCV era or to account for varying factors, such as temporal changes in the study population and vaccine utilisation [11].”
BackgroundInfluentialEffects of Vaccination on Invasive Pneumococcal Disease in South Africa
von Gottberg, A., de Gouveia, L., Tempia, S., Quan, V., Meiring, S., von Mollendorf, C., Madhi, S. A., Zell, E. R., Verani, J. R., O’Brien, K. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401914 · Cited by 373
Brueggemann, A. B., Peto, T. E. A., Crook, D. W., Butler, J. C., Kristinsson, K. G., & Spratt, B. G. (2004) · The Journal of Infectious Diseases · doi:10.1086/423820 · Cited by 329
Kim, L., McGee, L., Tomczyk, S., & Beall, B. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-15 · Cited by 285
Byington, C. L., Samore, M. H., Stoddard, G. J., Barlow, S., Daly, J., Korgenski, K., Firth, S., Glover, D., Jensen, J., Mason, E. O., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430604 · Cited by 230
Metcalf, B. J., Gertz, R. E., Gladstone, R. A., Walker, H., Sherwood, L. K., Jackson, D., Li, Z., Law, C., Hawkins, P. A., Chochua, S., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.08.027 · Cited by 203
Kellner, J. D., Vanderkooi, O. G., MacDonald, J., Church, D. L., Tyrrell, G. J., & Scheifele, D. W. (2009) · Clinical Infectious Diseases · doi:10.1086/599827 · Cited by 176
van Hoek, A. J., Sheppard, C. L., Andrews, N. J., Waight, P. A., Slack, M. P. E., Harrison, T. G., Ladhani, S. N., & Miller, E. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.017 · Cited by 172
Early Impact of 13-Valent Pneumococcal Conjugate Vaccine on Community-Acquired Pneumonia in Children
Angoulvant, F., Lévy, C., Grimprel, E., Varon, E., Lorrot, M., Biscardi, S., Minodier, P., Dommergues, M., Hees, L., Gillet, Y., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu006 · Cited by 145
van der Linden, M., Falkenhorst, G., Perniciaro, S., & Imöhl, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131494 · Cited by 142
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim, I. B., Hanage, W. P., Lipsitch, M., Shea, K. M., Stevenson, A. E., Finkelstein, J. A., Huang, S. S., Lee, G. M., KLEINMAN, K. P., & Pelton, S. I. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.032 · Cited by 138
Hausdorff, W. P., & Hanage, W. P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1118593 · Cited by 137
Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012
Lepoutre, A., Varon, E., Georges, S., Dorléans, F., Janoir, C., Gutmann, L., & Lévy-Bruhl, D. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.011 · Cited by 136
Hsu, K., Pelton, S. I., Karumuri, S., Heisey‐Grove, D., & Klein, J. O. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000148891.32134.36 · Cited by 133
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children
Olarte, L., Barson, W. J., Barson, R. M., Lin, P. L., Romero, J. R., Tan, T. Q., Givner, L. B., Bradley, J. S., Hoffman, J. A., Hultén, K. G., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ368 · Cited by 131
Calbo, E., Díaz, Á., Cañadell, E., Fábrega, J., Úriz, S., Xercavins, M., Morera, M.-A., Cuchí, E., Rodríguez‐Carballeira, M., Garau, J., et al. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.1502_1.x · Cited by 120
Loo, J. D., Conklin, L. M., Fleming-Dutra, K. E., Knoll, M. D., Park, D. E., Kirk, J., Goldblatt, D., O’Brien, K. L., & Whitney, C. G. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000084 · Cited by 112
Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013
Chiba, N., Morozumi, M., Shouji, M., Wajima, T., Iwata, S., Ubukata, K., & the Invasive Pneumococcal Diseases Surveillance Study Group (2014) · Emerging infectious diseases · doi:10.3201/eid2007.131485 · Cited by 105
Fleming-Dutra, K. E., Conklin, L. M., Loo, J. D., Knoll, M. D., Park, D. E., Kirk, J. M., Goldblatt, D., Whitney, C. G., & O’Brien, K. L. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000083 · Cited by 105
Nakano, S., Fujisawa, T., Ito, Y., Chang, B., Suga, S., Noguchi, T., Yamamoto, M., Matsumura, Y., Nagao, M., Takakura, S., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.015 · Cited by 101
Lee, G. M., Kleinman, K., Pelton, S. I., Hanage, W. P., Huang, S. S., Lakoma, M. D., Dutta-Linn, M. M., Croucher, N. J., Stevenson, A. E., & Finkelstein, J. A. (2013) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pit057 · Cited by 97
Moore, C. E., Paul, J., Foster, D., Mahar, S. A., Griffiths, D., Knox, K., Peto, T., Walker, A. S., & Crook, D. W. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu213 · Cited by 91
BLACK, S. B., France, E. K., Isaacman, D. J., Bracken, L., Lewis, E. M., Hansen, J. R., FIREMAN, B. H., AUSTRIAN, R. C., Graepel, J., Gray, S., et al. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318124a494 · Cited by 84
Valenzuela, M. T., O’Loughlin, R. E., de la Hoz, F., Gomez, E., Constenla, D. O., Sinha, A., Valencia, J. E., Flannery, B. L., & de Quadrós, C. A. (2009) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892009000300011 · Cited by 83
Suga, S., Chang, B., Asada, K., Akeda, H., Nishi, J., Okada, K., Wakiguchi, H., Maeda, A., Oda, M., Ishiwada, N., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.069 · Cited by 82
Sharma, D., Baughman, W. S., Holst, A., Thomas, S., Jackson, D. M., Carvalho, M. D. G., Beall, B., Satola, S. W., Jerris, R. R., Jain, S., et al. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182788fdd · Cited by 82
Weatherholtz, R., Millar, E. V., Moulton, L. H., Reid, R., Rudolph, K. M., Santosham, M., & O’Brien, K. L. (2010) · Clinical Infectious Diseases · doi:10.1086/651680 · Cited by 79
Varon, E., Cohen, R., Béchet, S., Doit, C., & Lévy, C. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.015 · Cited by 78
Navarro-Torné, A., Dias, J. G., Quinten, C., Hruba, F., Busana, M. C., Lopalco, P. L., Amato‐Gauci, A. J., & Celentano, L. P. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.066 · Cited by 74
Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine: A Population-Based Case-Control Study
Barricarte, A., Castilla, J., Gil-Setas, A., Torroba, L., Navarro-Alonso, J.-A., Irisarri, F., & Arriazu, M. (2007) · Clinical Infectious Diseases · doi:10.1086/516779 · Cited by 74
Knol, M. J., Wagenvoort, G. H. J., Sanders, E. A. M., Elberse, K. E. M., Vlaminckx, B. J. M., de Melker, H. E., & ENDE, A. V. D. (2015) · Emerging infectious diseases · doi:10.3201/eid2111.140780 · Cited by 74
Guevara, M., Ezpeleta, C., Gil-Setas, A., Torroba, L., Beristain, X., Aguinaga, A., García-Irure, J. J., Navascués, A., Cenoz, M. G., & Castilla, J. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.054 · Cited by 72
Lévy, C., Varon, E., Pïcard, C., Béchet, S., Martinot, A., Bonacorsi, S., & Cohen, R. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000451 · Cited by 60
Jaiswal, N., Singh, M., Das, R. R., Jindal, I., Agarwal, A. K., Thumburu, K. K., Kumar, A., & Chauhan, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108617 · Cited by 57
Lévy, C., Varon, E., Bingen, É., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f4cf69 · Cited by 51
Muñoz‐Almagro, C., Ciruela, P., Esteva, C., Marco, F., Navarro, M., Bartolomé, R. M., Sauca, G., Gallés, C., Morta, M., Ballester, F., et al. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.06.002 · Cited by 50
Camilli, R., Daprai, L., Cavrini, F., Lombardo, D., D’Ambrosio, F., Grosso, M. D., Vescio, M. F., Landini, M. P., Pascucci, M. G., Torresani, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076309 · Cited by 48
Wals, P. D., Lefebvre, B., Defay, F., Deceuninck, G., & Boulianne, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.017 · Cited by 48
Williams, S. R., Mernagh, P. J., Lee, M. H. T., & Tan, J. T. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb04192.x · Cited by 47
Imöhl, M., Møller, J. K., Reinert, R. R., Perniciaro, S., van der Linden, M., & Aktaş, O. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0787-1 · Cited by 40
Impact of the Conjugate Pneumococcal Vaccine in Arkansas
Schutze, G. E., Tucker, N. C., & Mason, E. O. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000145478.36236.1e · Cited by 39
Pérez‐Trallero, E., Marimón, J. M., Ercibengoa, M., Vicente, D. A., & Pérez‐Yarza, E. G. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0693-1 · Cited by 38
Parra-Barrera, E. L., de la Hoz, F., Díaz, P., Sanabria, O. M., Realpe, M. E., & Moreno, J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.074 · Cited by 38
Shibl, A. M., Memish, Z. A., & Al-Kattan, K. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.030 · Cited by 35
Ishiwada, N., Hishiki, H., Nagasawa, K., Naito, S., Sato, Y., Chang, B., Sasaki, Y., Kimura, K., Ohnishi, M., & Shibayama, K. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.100 · Cited by 35
Doit, C., Mariani‐Kurkdjian, P., Mahjoub‐Messai, F., Bidet, P., Bonacorsi, S., Carol, A., Varon, E., & Bingen, É. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.10.012 · Cited by 30
Croney, C. M., Coats, M. T., Nahm, M. H., Briles, D. E., & Crain, M. J. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05671-11 · Cited by 29
Ceyhan, M., Gürler, N., Yaman, A., et al. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00526-10 · Cited by 16
Herrero-Goñi, M., Alcalde, M., Gómez, B., et al. (2011) · European Journal of Emergency Medicine · doi:10.1097/mej.0b013e3283484bbc · Cited by 14
Cited by
Lo, S. W., Gladstone, R. A., van Tonder, A. J., Lees, J. A., du Plessis, M., Benisty, R., Givon-Lavi, N., Hawkins, P. A., Cornick, J. E., Kwambana-Adams, B., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30297-x · Cited by 291
Metadata
- Authors
- Balsells, E., Guillot, L., Nair, H., & Kyaw, M. H.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-09
- Volume
- 12
- Issue
- 5
- Pages
- e0177113
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2613751645
- Cited by
- 393
- References
- 57
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.